CC 96673
Alternative Names: CC-96673Latest Information Update: 03 Feb 2022
At a glance
- Originator Celgene Corporation
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-Hodgkin's lymphoma
Most Recent Events
- 21 Jan 2022 Phase-I clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (IV) (NCT04860466)
- 30 Apr 2021 Preclinical trials in Non-Hodgkin's lymphoma in USA (IV) prior to April 2021
- 29 Apr 2021 Celgene Corporation plans phase I trial for Non-Hodgkin's lymphoma (Second-line therapy or greater) (IV, Infusion) in April 2021 (NCT04860466)